Vince O’Neill - Concepedia

Author

Vince O’Neill

Exosome Diagnostics (United States)

Also Known As

V O'Neill, V. J. O'Neill, V. O'Neill, Vikki O'Neill, Vince J. O'Neill, Vince O'Neill, Vince O’Neill

Publications

955

Citations

H-Index

Concepts

All Affiliations

Exosome Diagnostics (United States)New Jersey Urology Johns Hopkins University University of Colorado Cancer Center Icahn School of Medicine at Mount Sinai

About

Vince O’Neill is an author at Exosome Diagnostics (United States) specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	220
2	Pathology	3	3	197
3	Pharmacology	3	3	36
4	Health Sciences	2	2	26
5	Cell Biology	1	1	14

Vince O’Neill

Publications

927

Citations

H-Index

Page 1

	Year	Citations
A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy James M. McKiernan, Michael Donovan, Vince O’Neill, JAMA Oncology	2016	635
A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result Michael Donovan, Mikkel Noerholm, Stefan Bentink, Prostate Cancer and Prostatic Diseases UrologyErg Exosomal RnaGenitourinary CancerMedicinePathology	2015	170
DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma Allison A. Fitzgerald, Shangzi Wang, Veena R. Agarwal, Journal for ImmunoTherapy of Cancer	2021	72
Abstract B136: Plasma EGFR mutation detection using a combined exosomal RNA and circulating tumor DNA approach in patients with acquired resistance to first-generation EGFR-TKIs Anne K. Krug, Chris Karlovich, Tina Koestler, Molecular Cancer Therapeutics Kinase InhibitorsPathologyCancer BiologyTumor BiologyExosomal Rna	2015	14
A three-part, phase I, dose-escalation study of GSK1120212, a potent MEK inhibitor, administered orally to subjects with solid tumors or lymphoma Dawn Thompson, K. T. Flaherty, W. Messersmith, Journal of Clinical Oncology Dose-escalation StudyTumor BiologyLymphoid NeoplasiaPart 1Oncology	2009	13
Fluorescence in situ hybridization (FISH) subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in NSCLC Fred R. Hirsch, Marileila Varella‐Garcia, Paul A. Bunn, Journal of Clinical Oncology Advanced NsclcGene AmplificationMedicineCancer ManagementPharmacology	2007	12
53 POSTER A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab (Avastin®) in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride (Tarceva®) compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer Roy S. Herbst, Vince O’Neill, Louis Fehrenbacher, European Journal of Cancer Supplements MedicinePharmacologyClinical TrialsErlotinib HydrochlorideImmune Checkpoint Inhibitor	2006	11

Page 1